Trial Outcomes & Findings for CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer (NCT NCT01218867)

Last Updated: 2019-12-10

Results Overview

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment starts or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

24 participants

Primary outcome timeframe

5 years

Results posted on

2019-12-10

Participant Flow

Twenty-four participants were enrolled but one participant was not treated due to a new cancer diagnosis which made the participant ineligible for this protocol.

Participant milestones

Participant milestones
Measure	Cohort 1 - 1 x 10(6) Cells (High Dose IL-2) Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) cluster of differentiation 8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 - 3 x 10(6) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 - 1 x 10(7) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 - 3 x 10(7) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 - 1 x 10(8) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 - 3 x 10(8) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 - 1 x 10(9) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Overall Study STARTED	1	1	3	1	1	1	4	3	3	4	2
Overall Study COMPLETED	1	1	3	1	1	1	3	3	3	4	2
Overall Study NOT COMPLETED	0	0	0	0	0	0	1	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort 1 - 1 x 10(6) Cells (High Dose IL-2) Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) cluster of differentiation 8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 - 3 x 10(6) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 - 1 x 10(7) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 - 3 x 10(7) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 - 1 x 10(8) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 - 3 x 10(8) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 - 1 x 10(9) Cells (High Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2) Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Overall Study Death during treatment	0	0	0	0	0	0	1	0	0	0	0

Baseline Characteristics

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort 1 - 1 x 10(6) Cells (High Dose IL-2) n=1 Participants Anti-vascular endothelial growth factor receptor 2 (VEGFR2) Chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 - 3 x 10(6) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 - 1 x 10(7) Cells (High Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 - 3 x 10(7) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 - 1 x 10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 - 3 x 10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 - 1 x 10(9) Cells (High Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2) n=2 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Total n=24 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	3 Participants n=6 Participants	4 Participants n=64 Participants	2 Participants n=17 Participants	23 Participants n=21 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	1 Participants n=21 Participants
Age, Continuous	61.0 years STANDARD_DEVIATION 0 • n=5 Participants	51.0 years STANDARD_DEVIATION 0 • n=7 Participants	52.7 years STANDARD_DEVIATION 12.1 • n=5 Participants	65.0 years STANDARD_DEVIATION 0 • n=4 Participants	55.0 years STANDARD_DEVIATION 0 • n=21 Participants	35.0 years STANDARD_DEVIATION 0 • n=10 Participants	45.5 years STANDARD_DEVIATION 11.3 • n=115 Participants	37.0 years STANDARD_DEVIATION 18.0 • n=6 Participants	54.7 years STANDARD_DEVIATION 11.9 • n=6 Participants	46.3 years STANDARD_DEVIATION 5.6 • n=64 Participants	41.5 years STANDARD_DEVIATION 10.6 • n=17 Participants	47.9 years STANDARD_DEVIATION 11.8 • n=21 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	1 Participants n=6 Participants	1 Participants n=6 Participants	2 Participants n=64 Participants	0 Participants n=17 Participants	7 Participants n=21 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	3 Participants n=115 Participants	2 Participants n=6 Participants	2 Participants n=6 Participants	2 Participants n=64 Participants	2 Participants n=17 Participants	17 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	1 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	2 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	2 Participants n=6 Participants	4 Participants n=64 Participants	2 Participants n=17 Participants	22 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	3 Participants n=115 Participants	2 Participants n=6 Participants	3 Participants n=6 Participants	4 Participants n=64 Participants	1 Participants n=17 Participants	20 Participants n=21 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	1 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	1 Participants n=17 Participants	4 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants
Region of Enrollment United States	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	4 Participants n=115 Participants	3 Participants n=6 Participants	3 Participants n=6 Participants	4 Participants n=64 Participants	2 Participants n=17 Participants	24 Participants n=21 Participants

PRIMARY outcome

Timeframe: 5 years

Outcome measures

Outcome measures
Measure	Cohort 1 - 1x10(6) Cells (High Dose IL-2) n=1 Participants Anti-vascular endothelial growth factor receptor 2 (VEGFR2) Chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 - 3x10(6) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 - 1x10(7) Cells (High Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 - 3x10(7) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 - 1x10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 - 3x10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 - 1x10(9) Cells (High Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 - 1x10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 - 3x10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 - 1x10(10) Cells (Low Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 - 3x10(10) Cells (Low Dose IL-2) n=2 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Number of Participants With a Response to Therapy Complete Response (CR)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Response to Therapy Partial Response (PR)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With a Response to Therapy Stable Disease (SD)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Response to Therapy Progressive Disease (PD)	1 Participants	1 Participants	3 Participants	1 Participants	1 Participants	1 Participants	3 Participants	3 Participants	3 Participants	3 Participants	2 Participants

SECONDARY outcome

Timeframe: Date treatment consent signed to date off study, approximately, 33 months and 25 days

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Outcome measures

Outcome measures
Measure	Cohort 1 - 1x10(6) Cells (High Dose IL-2) n=1 Participants Anti-vascular endothelial growth factor receptor 2 (VEGFR2) Chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 - 3x10(6) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 - 1x10(7) Cells (High Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 - 3x10(7) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 - 1x10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 - 3x10(8) Cells (High Dose IL-2) n=1 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 - 1x10(9) Cells (High Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 - 1x10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 - 3x10(9) Cells (Low Dose IL-2) n=3 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 - 1x10(10) Cells (Low Dose IL-2) n=4 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 - 3x10(10) Cells (Low Dose IL-2) n=2 Participants Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Number of Participants With Serious and Non-Serious Adverse Events	1 Participants	1 Participants	3 Participants	1 Participants	1 Participants	1 Participants	4 Participants	3 Participants	3 Participants	3 Participants	2 Participants

SECONDARY outcome

Timeframe: 6 years

Population: This outcome measure was not done due to the lack of a minimum number (e.g. 4) of required durable responses in the participants. A durable response is defined as a complete response, partial response, or stable disease in at least 4 participants.

Immunological monitoring using both tetramer analysis and staining for the T cell receptor (TCR) will be used to augment polymerase chain reaction (PCR)-based analysis. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells.

Outcome measures

Other events: 3 other events

Deaths: 0 deaths

Cohort 11 (3x10(10) Cells (Low Dose IL-2)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Cohort 1 (1x10(6) Cells (High Dose IL-2) n=1 participants at risk Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 (3x10(6) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 (1x10(7) Cells (High Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 (3x10(7) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 (1x10(8) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 (1x10(8) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 (1x10(9) Cells (High Dose IL-2) n=4 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 (1x10(9) Cells (Low Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 (3x10(9) Cells (Low Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 (1x10(10) Cells (Low Dose IL-2) n=4 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 (3x10(10) Cells (Low Dose IL-2) n=2 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Gastrointestinal disorders Nausea	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Gastrointestinal disorders Vomiting	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
General disorders Pain	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders ALT, SGPT (serum glutamic pyruvic transaminase)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders AST, SGOT (serum glutamic oxaloacetic transaminase)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Bilirubin (hyperbilirubinemia)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Infections and infestations Infection	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days

Other adverse events

Other adverse events
Measure	Cohort 1 (1x10(6) Cells (High Dose IL-2) n=1 participants at risk Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 2 (3x10(6) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 3 (1x10(7) Cells (High Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 4 (3x10(7) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 5 (1x10(8) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 6 (1x10(8) Cells (High Dose IL-2) n=1 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 7 (1x10(9) Cells (High Dose IL-2) n=4 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 8 (1x10(9) Cells (Low Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 9 (3x10(9) Cells (Low Dose IL-2) n=3 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 10 (1x10(10) Cells (Low Dose IL-2) n=4 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days	Cohort 11 (3x10(10) Cells (Low Dose IL-2) n=2 participants at risk Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1) Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses) Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days
Metabolism and nutrition disorders Creatinine	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders Hemoglobin	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	66.7% 2/3 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders Leukocytes (Total WBC)	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 4/4 • Number of events 4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 2/2 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders Lymphopenia	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 4/4 • Number of events 4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 2/2 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders Neutrophils/granulocytes (ANC/AGC)	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 4/4 • Number of events 4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 2/2 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders Platelets	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 4/4 • Number of events 4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	66.7% 2/3 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Cardiac disorders Supraventricular and nodal arrhythmia	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
General disorders Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Infections and infestations Infection	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Albumin, serum-low (hypoalbuminemia)	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Dyspnea (shortness of breath)	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Blood and lymphatic system disorders PTT (Partial Thromboplstin Time)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
General disorders Fatigue (asthenia, lethargy, malaise)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Phosphate, serum-low (hypophosphatemia)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	66.7% 2/3 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Cardiac disorders Hypotension	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Infections and infestations Febrile neutropenia	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	75.0% 3/4 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 3/3 • Number of events 3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Nervous system disorders Confusion	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Gastrointestinal disorders Dehydration	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Gastrointestinal disorders Nausea	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Hepatobiliary disorders Liver dysfunction/failure (clinical)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Alkaline phosphatase	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Calcium, serum-low (hypocalcemia)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Potassium, serum-low (hypokalemia)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Nervous system disorders Psychosis (hallucinations/delusions)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	100.0% 1/1 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Ear and labyrinth disorders Hearing: patients with/without baseline audiogram and enrolled in a monitoring program	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Gastrointestinal disorders Constipation	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Gastrointestinal disorders Mucositis/stomatitis (clinical exam)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Renal and urinary disorders Hemorrhage, GU	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Hemorrhage, pulmonary/upper respiratory	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders ALT, SGPT (serum glutamic pyruvic transaminase)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 1/2 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders AST, SGOT (serum glutamic oxaloacetic transaminase)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Metabolism and nutrition disorders Uric acid, serum-high (hyperuricemia)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Nervous system disorders Somnolence/depressed level of consciousness	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Eye disorders Ocular/Visual-Other (vision changes)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
General disorders Pain	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Renal and urinary disorders Renal failure	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
General disorders Syndromes - Other (hemaphogocytic syndrome)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Vascular disorders Acute vascular leak syndrome	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	66.7% 2/3 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	50.0% 2/4 • Number of events 2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Nervous system disorders Syncope (fainting)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Pleural effusion (non-malignant)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Pneumonitis/pulmonary infiltrates	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	33.3% 1/3 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days
Renal and urinary disorders Renal/Genitourinary - Other (low urine output)	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/4 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/3 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	25.0% 1/4 • Number of events 1 • Date treatment consent signed to date off study, approximately, 33 months and 25 days	0.00% 0/2 • Date treatment consent signed to date off study, approximately, 33 months and 25 days

Additional Information

Dr. Steven Rosenberg

National Cancer Institute

Phone: 301- 496-4164

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place